Splicing inhibition induces gene expression through canonical NF-κB pathway and extracellular signal-related kinase activation

被引:8
作者
Khan, Khalid [1 ,3 ]
Schneider-Poetsch, Tilman [1 ]
Ishfaq, Muhammad [1 ]
Ito, Akihiro [1 ,2 ,3 ]
Yoshimoto, Rei [1 ]
Mukaida, Naofumi [4 ]
Yoshida, Minoru [1 ,2 ,3 ]
机构
[1] RIKEN, Chem Genet Lab, Wako, Saitama 3510198, Japan
[2] RIKEN, Ctr Sustainable Resource Sci, Chem Genom Res Grp, Wako, Saitama 3510198, Japan
[3] Saitama Univ, Grad Sch Sci & Engn, Sakura Ku, Saitama 3388570, Japan
[4] Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa 9201192, Japan
关键词
Spliceostatin A; Extracellular signal-regulated protein kinase; NF-kappa B; CYSTIC-FIBROSIS CELLS; ANTITUMOR SUBSTANCES; INTERLEUKIN-8; GENE; FR901464; PROMOTER; ALPHA; ERK; SPLICEOSTATIN; ENHANCER; MICE;
D O I
10.1016/j.febslet.2014.02.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Splicing, a process for mRNA maturation, is essential for correct gene expression after transcription. However, recent studies also suggest that splicing affects transcription, but its mechanism remains elusive. We previously reported that treatment with spliceostatin A (SSA), a specific splicing inhibitor targeting the splicing factor SF3b, leads to transcriptional activation of a small subset of genes. To investigate the underlying mechanism we utilized luciferase reporters driven by the Interleukin 8 (IL-8) and cytomegalovirus (CMV) promoters, as both recruit a similar set of transcription factors. We also found that SSA treatment led to increased extracellular signal-regulated protein kinase (ERK) activity and that chemical inhibition of ERK also led to decreased promoter activation. Systematic deletion studies suggested that NF-kappa B activation is mainly responsible for SSA-induced promoters activation. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1053 / 1057
页数:5
相关论文
共 23 条
  • [1] Adenovirus type 7 induces interleukin-8 production via activation of extracellular regulated kinase 1/2
    Alcorn, MJ
    Booth, JL
    Coggeshall, KM
    Metcalf, JP
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (14) : 6450 - 6459
  • [2] Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells
    Elliott, CL
    Allport, VC
    Loudon, JAZ
    Wu, GD
    Bennett, PR
    [J]. MOLECULAR HUMAN REPRODUCTION, 2001, 7 (08) : 787 - 790
  • [3] Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF
    Furumai, Ryohei
    Uchida, Kazuyo
    Komi, Yusuke
    Yoneyama, Misao
    Ishigami, Ken
    Watanabe, Hidenori
    Kojima, Soichi
    Yoshida, Minoru
    [J]. CANCER SCIENCE, 2010, 101 (11) : 2483 - 2489
  • [4] Synergistic activation of the CMV promoter by NF-κB P50 and PKG
    He, B
    Weber, GF
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 321 (01) : 13 - 20
  • [5] Hehner SP, 1999, J IMMUNOL, V163, P5617
  • [6] Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847
  • [7] PHORBOL ESTER INDUCES THE TRANSCRIPTIONAL STIMULATORY ACTIVITY OF THE SV40 ENHANCER
    IMBRA, RJ
    KARIN, M
    [J]. NATURE, 1986, 323 (6088) : 555 - 558
  • [8] Temporal control of NF-κB activation by ERK differentially regulates interleukin-1β-induced gene expression
    Jiang, BB
    Xu, SQ
    Hou, XY
    Pimentel, DR
    Brecher, P
    Cohen, RA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (02) : 1323 - 1329
  • [9] Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA
    Kaida, Daisuke
    Motoyoshi, Hajime
    Tashiro, Etsu
    Nojima, Takayuki
    Hagiwara, Masatoshi
    Ishigami, Ken
    Watanabe, Hidenori
    Kitahara, Takeshi
    Yoshida, Tatsuhiko
    Nakajima, Hidenori
    Tani, Tokio
    Horinouchi, Sueharu
    Yoshida, Minoru
    [J]. NATURE CHEMICAL BIOLOGY, 2007, 3 (09) : 576 - 583
  • [10] Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
    Kim, YB
    Lee, KH
    Sugita, K
    Yoshida, M
    Horinouchi, S
    [J]. ONCOGENE, 1999, 18 (15) : 2461 - 2470